

# Scaling up to meet global demand




We have moved with unprecedented urgency throughout the COVID-19 pandemic to rapidly build our capacity to produce our investigational oral antiviral COVID-19 medicine.

## Investing at risk to meet the urgent health need

Our manufacturing teams started to produce our investigational oral antiviral COVID-19 medicine at scale in late 2020, before we had substantial clinical data.

Standing up the largest manufacturing capacity in under 12 months in our company's history



### May 2020

Merck announces agreement with Ridgeback Biotherapeutics to develop a novel, oral antiviral candidate

### July 2020

Merck begins producing clinical supplies and initiates plans for scale up

### December 2020


Merck achieves production of 25,000 courses of treatment

### November 2021

First doses shipped to the UK

### March 2022

Doses delivered to over 30 markets



## Working around the globe


We are utilizing our global network, including manufacturing sites across 3 continents:

- USA
- Puerto Rico
- Canada
- Netherlands
- Italy
- China
- Japan
- Ireland
- India

Our supply chain is comprised of **17 internal and external plants globally**. We use a diverse network of internal and external suppliers, packaging plants and distributors.

## Working with generic manufacturers

We recognize the role that generic medicines can play in meeting the needs of many people in the developing world. As evidenced by our voluntary licensing agreements with established Indian generics manufacturers and with the Medicines Patent Pool, we are committed to expanding access to medicines globally, including through the availability of high-quality generics in developing countries.



The pandemic continues to be an unrivaled global health challenge. We are moving with urgency and rigor to bring our investigational oral antiviral COVID-19 medicine to patients as quickly as we can.

